PE Anti-MIP-1 alpha/CCL3 + CCL3L1 antibody [EPR22529-19]

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary

MIP-1 alpha also known as CCL3 or CCL3L1 is a chemokine with important roles in immune regulation. It has a molecular mass of approximately 7.8 kDa. This protein is expressed mainly in immune cells like macrophages T cells and natural killer (NK) cells. The expression of MIP-1 alpha occurs in response to inflammatory signals and it acts to recruit other immune cells to the site of infection or injury. Its function is essential for orchestrating the cellular movements during immune surveillance and defensive responses.

Biological function summary

The MIP-1 alpha functions as a chemotactic cytokine. It binds to receptors like CCR1 and CCR5 on the surface of target cells resulting in activation and migration toward areas of inflammation. MIP-1 alpha does not form a complex with other proteins; however its interactions with its receptors are vital for signal transduction. It also promotes the production of additional inflammatory cytokines contributing to amplifying immune responses. The chemotactic properties of MIP-1 alpha make it an important player in the body's defense against pathogens.

Pathways

MIP-1 alpha is involved in important immune pathways like the NF-kB signaling pathway. This pathway plays a significant role in immune cell activation and the inflammatory response. MIP-1 alpha interacts with other chemokines like CCL4 (MIP-1 beta) which shares similar functions and binds to CCR5. The coordinated activities of these chemokines enhance the recruitment and activation of various leukocyte populations facilitating an effective immune response.

Associated diseases and disorders

MIP-1 alpha exhibits a connection to inflammatory diseases such as rheumatoid arthritis and HIV infection. In rheumatoid arthritis MIP-1 alpha contributes to joint inflammation and damage by attracting immune cells to synovial joints. In the context of HIV it interacts with the CCR5 receptor affecting viral entry into CD4+ T cells. The inhibition of MIP-1 alpha and its interaction with CCR5 provides a therapeutic strategy in controlling HIV progression. These associations highlight the chemokine's impact on both autoimmune disorders and infectious diseases.